Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma
Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma
复制标题
用于肝细胞癌靶向化疗的同型细胞膜包裹仿生纳米载体
DOI：
10.7150/thno.34837
复制
发表时间：
2019-01-01
期刊：
影响因子：
12.4
通讯作者：
Tang, Bo
中科院分区：
文献类型：
--
作者：
Liu, Xiaojun;Sun, Yingxue;Tang, Bo
目的：肝细胞癌（Hepatocellular carcinoma，HCC）是世界上第三常见的恶性肿瘤，其死亡率居世界首位。为提高肝癌的化疗疗效，需要一种具有主动靶向、高效、免疫逃逸等特点的给药系统。方法：利用同种型癌细胞膜制备药物纳米载体，用于肝癌的靶向化疗。在结构上，同型HepG 2细胞膜被用作外衣，聚（乳酸-共-乙醇酸）（PLGA）纳米颗粒作为核心，产生纳米载体HepM-PLGA。结果：HepM-PLGA纳米粒对HepG 2细胞具有良好的靶向性。多柔比星（Dox）在HepM-PLGA载体上具有高的载药效率和显著的体外治疗效果。在体内实验中，HepM-PLGA将Dox直接递送到裸鼠的肿瘤病灶，治疗后肿瘤体积减小约90%。结论：我们利用同型癌细胞膜研制了一种药物纳米载体，用于肝癌的靶向化疗，具有良好的主动靶向能力。这种仿生平台不仅有效地治疗HCC，而且通过改变相应的同型癌细胞膜为治疗其他癌症提供了一种合理的策略。
Goals: Hepatocellular carcinoma (HCC) has been reported to be the third most common malignant tumor and has the highest rate of mortality. To increase the chemotherapy efficacy of HCC, a drug delivery system featured with desirable active targeting ability, delivery efficiency and immune evasion is in high demand. Methods: We have developed a drug nanocarrier by utilizing a homotypic cancer cell membrane for targeted chemotherapy of HCC. Structurally, the homotypic HepG2 cell membrane was used as the cloak, and a poly (lactic-co-glycolic acid) (PLGA) nanoparticle as the core, resulting in the nanocarrier HepM-PLGA. Results: The HepM-PLGA nanoparticles exhibit excellent targeting ability toward HepG2 cells. Doxorubicin (Dox) carried by HepM-PLGA possesses high delivery efficiency and a remarkable in vitro therapeutic effect. In in vivo experiments, HepM-PLGA delivers Dox directly to the tumor lesion of nude mice, and tumor volume decreases by approximately 90% after treatment. Conclusion: We have developed a drug nanocarrier by utilizing a homotypic cancer cell membrane for targeted chemotherapy of HCC with excellent active targeting ability. This biomimetic platform not only effectively treats HCC but also provides a sound strategy for the treatment of other cancers via changes in the corresponding homotypic cancer cell membrane.